{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Capricor Therapeutics, Inc.
Capricor Therapeutics Hits Day High with Strong 9.04% Intraday Surge
Capricor Therapeutics, Inc. has experienced notable stock movement, gaining 9.04% today and achieving an intraday high of USD 36.49. Over the past week, the stock has surged by 29.26%, with a remarkable one-year increase of 170.66%, despite ongoing financial challenges and negative quarterly results.
Capricor Therapeutics Hits Day High with Strong 9.78% Intraday Surge
Capricor Therapeutics, Inc. has seen a notable rise in its stock performance, gaining 9.78% today and achieving an intraday high of USD 31.41. Over the past year, the stock has surged by 139.11%, despite reporting negative financial results for the last four quarters and declining key metrics.
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise
Capricor Therapeutics, Inc. has experienced a significant gain today, contrasting with the broader market's modest increase. Despite a strong monthly performance, the company has reported negative financial results for four consecutive quarters, with substantial losses and a high price-to-book ratio, raising concerns among market observers.
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price
Capricor Therapeutics, Inc. has seen a significant stock increase today, contrasting with a decline in the S&P 500. While the company has shown impressive long-term growth, it faces financial challenges, including negative quarterly results and low operating cash flow, indicating complexities in its market position.
Capricor Therapeutics Hits New 52-Week Low at $4.40 Amid Financial Struggles
Capricor Therapeutics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance. The company reported a 46.91% drop in net sales for the first nine months, alongside a negative operating cash flow and rising raw material costs, indicating ongoing financial challenges.
Capricor Therapeutics Hits 52-Week Low at $5.43 Amid Financial Struggles
Capricor Therapeutics, Inc. has hit a new 52-week low, reflecting a significant decline in its stock value over the past year. The company reported a 46.91% drop in net sales and a negative operating cash flow, compounded by rising raw material costs. Its financial metrics indicate ongoing challenges.
Is Capricor Therapeutics, Inc. technically bullish or bearish?
As of July 17, 2025, Capricor Therapeutics, Inc. shows a bearish trend with weak strength indicators, despite a 25% one-year return, as year-to-date performance is down 53.62%, significantly underperforming the S&P 500.
Is Capricor Therapeutics, Inc. overvalued or undervalued?
As of November 10, 2022, Capricor Therapeutics, Inc. is considered risky and overvalued, with a high Price to Book Value of 5.10, negative EV to EBIT and EBITDA ratios, a troubling -43.14% Return on Equity, and a year-to-date return of -53.62%, significantly underperforming the S&P 500.
Is Capricor Therapeutics, Inc. overvalued or undervalued?
As of November 10, 2022, Capricor Therapeutics, Inc. is considered risky and overvalued due to its negative P/E ratio, high price-to-book value, and poor stock performance, especially compared to peers like Chimerix and CytomX.
Is Capricor Therapeutics, Inc. technically bullish or bearish?
As of June 20, 2025, Capricor Therapeutics, Inc. shows a bearish trend with dominant negative indicators, despite some mixed signals in the monthly timeframe.
Who are in the management team of Capricor Therapeutics, Inc.?
As of March 2022, the management team of Capricor Therapeutics, Inc. includes Dr. Frank Litvack (Independent Executive Chairman), Dr. Linda Marban (President and CEO), and several independent directors: Mr. Joshua Kazam, Mr. Earl Collier, Mr. George Dunbar, Mr. Louis Grasmick, and Mr. Louis Manzo. They oversee the company's strategic direction and operations.
What does Capricor Therapeutics, Inc. do?
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicine therapies for cardiovascular diseases. As of March 2025, it has a market cap of $557.18 million and reported a net profit loss of $24 million.
How big is Capricor Therapeutics, Inc.?
As of Jun 18, Capricor Therapeutics, Inc. has a market capitalization of 557.18 million, with net sales of 17.36 million and a net profit of -55.07 million over the latest four quarters. The company reported shareholder's funds of 145.46 million and total assets of 170.48 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
